Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease-Reference-Cited by-同舟云学术

Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease

Published:2022-10-26 Issue:21 Volume:65 Page:14957-14969
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Sun Yi¹,Xu Lijuan²³,Shao Hongming³,Quan Danni²,Mo Zixin¹,Wang Jue¹,Zhang Wannian²³,Yu Jianqiang²,Zhuang Chunlin²³^ORCID,Xu Ke⁴⁵

Affiliation:

1. Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China

2. School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China

3. School of Pharmacy, Second Military Medical University, Shanghai 200433, China

4. Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai 200434, China

5. Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Shanghai 200434, China

Funder

Ministry of Education of the People's Republic of China

Ministry of Science and Technology of the People's Republic of China

Science and Technology Commission of Shanghai Municipality

National Natural Science Foundation of China

Tongji University

Shanghai Health Commission Clinical Research Special Youth Project

Shanghai Shuguang Project

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01478

Reference44 articles.

1. Melatonin in Alzheimer’s Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer’s Neuropathology

2. A Multilevel View of the Development of Alzheimer’s Disease

3. Recent Progress in Alzheimer’s Disease Research, Part 1: Pathology

4. Oxidative stress: The core pathogenesis and mechanism of Alzheimer’s disease

5. Receptor-Interacting Protein Kinase 1 (RIPK1) as a Potential Therapeutic Target: An Overview of Its Possible Role in the Pathogenesis of Alzheimer's Disease

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development;European Journal of Medicinal Chemistry;2024-02

2. Discovery of novel biaryl benzoxazepinones as dual-mode receptor-interacting protein kinase-1 (RIPK1) inhibitors;Bioorganic & Medicinal Chemistry;2024-02

3. Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases;Cell Death & Disease;2023-12-21

4. Insight from Linker Investigations: Discovery of a Novel Phenylbenzothiazole Necroptosis Inhibitor Targeting Receptor-Interacting Protein Kinase 1 (RIPK1) from a Phenoxybenzothiazole Compound with Dual RIPK1/3 Targeting Activity;Journal of Medicinal Chemistry;2023-11-02

5. Analysis on benzothiazole necroptosis inhibitors with chiral substitutions in the solvent-accessible region of RIP kinase domain;Bioorganic Chemistry;2023-08